Publications

Navada S.C., Garcia-Manero, G., et al. (2020) Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. Leukemia Research 94, July 2020

Navada, S.C., Fruchtman, S.M., et al. (2018) A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia. Leukemia Research 64:10-16

Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N and Silverman LR (2016) Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncology 17(4):496-508

Silverman LR, Greenberg PL, Raza A, Olnes MJ, Holland JF, Reddy EP, Maniar M, Wilhelm F (2014) Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol:ePub 29Apr2014

Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, Keysar SB, Freas E, Aisner DL, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, Jimeno A (2014) Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res 20: 1656-65

Komrokji RS, Raza A, Lancet JE, Ren C, Taft D, Maniar M, Wilhelm F, List AF (2013) Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. British Journal of Haematology 162: 517-524

Ohnuma T, Lehrer D, Ren C, Cho SY, Maniar M, Silverman L, Sung M, Gretz HF 3rd, Benisovich V, Navada S, Akahoho E, Wilck E, Taft DR, Roboz J, Wilhelm F, Holland JF (2013) Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. American Journal of Cancer Research 3: 323-338

Roschewski M, Farooqui M, Aue G, Wilhelm F, Wiestner A (2013) Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies. Leukemia: ePub 3Mar2013 

Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A (2012) Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer. Clinical Cancer Research18: 2048-2055

Olnes MJ, Shenoy A, Weinstein B, Pfannes L, Loeliger K, Tucker Z, Tian X, Kwak M, Wilhelm F, Yong AS, Maric I, Maniar M, Scheinberg P, Groopman J, Young NS, Sloand EM (2012) Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leukemia Res 36: 982-989

Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL (2012) Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leukemia Res 36: 98-103

Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, Donehower RC (2008) Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 26: 5504-5510

Flemming, A. (2016) RAS mimetic revealed. Nature Reviews Drug Discovery published online June 1, 2016

Alessandrino, E. (2016) Novel trial designs for high-risk myelodyplastic sydromes. Lancet Oncology 17:4, 410-412

Raza A, Ali AM, Reddy MVR, Hoffman BS, Petrone ME, Maniar M, Pinheiro RF, Coutinho DF and Fruchtman SM (2016) Rigosertib in myelodysplastic syndromes (MDS). Expert Opinion on Orphan Drugs 4(9): 981-988

Navada SC and Silverman LR (2016) The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes. Expert Review of Anticancer Therapies 16(8):805-810

List AF (2012) New therapeutics for myelodysplastic syndromes. Leukemia Res 36: 1470-1474

Mundle SD (2012) Editorial:  Targeting cyclin D1 for high risk myelodysplastic syndromes. Leukemia Res 36: 964-965

Bouchie A (2011) Rigosertib's arresting story. BioCentury 18July2011: A6

Kumar CC (2011) Genetic Abnormalities and Challenges in the Treatment of Acute Myeloid Leukemia. Genes & Cancer 2: 95-107

Taft DR, Dave R, Gillum AM, Maniar M (2011) ON 01910.Na. Drugs of the Future 36: 433-440

Vuong L (2010) Estybon May Be Effective For MDS Patients Who Experience Vidaza and Dacogen Failure (ASH 2010). The MDS Beacon: On-Line posting 13 Dec 2010

Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, Baker SJ, Cosenza SC, Basu I, Gupta YK, Reddy MV, Ueno L, Hart JR, Vogt PK, Mulholland D, Guha C, Aggarwal AK and Reddy EP (2016) A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Cell 165(3): 643-655

Agoni L, Basu I, Gupta S, Alfieri A, Gambino A, Goldberg GL, Reddy EP, Guha C (2014) Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo. Int J Radiat Oncol Biol Phys:ePub 18Feb2014

Pallela VR, Mallireddigari MR, Cosenza SC, Akula B, Subbaiah DR, Reddy EP, Reddy MV (2013) Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910.Na (Rigosertib(R)), a phase III clinical stage anti-cancer agent. Organic & Biomolecular Chemistry 11: 1964-1977

Chapman CM, Sun X, Roschewski M, Aue G, Farooqui M, Stennett L, Gibellini F, Arthur D, Perez-Galan P, Wiestner A (2012) ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress. Clinical Cancer Research 18: 1979-1991

Nuthalapati S, Zhou Q, Guo P, Lv H, Cosenza S, Reddy MV, Reddy EP, Gallo JM (2012) Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon) and ON013105, for brain tumor chemotherapy. Pharm Res 29: 2499-2511

Lu M, Merali S, Gordon R, Jiang J-D, Li Y, Mandeli J, Duan X, Fallon J, Holland JF (2011) Prevention of Doxorubicin Cardiopathic Changes by a Benzyl Styryl Sulfone in Mice. Genes & Cancer 2: 985-992

Nuthalapati S, Guo P, Zhou Q, Reddy MVR, Reddy EP, Gallo JM (2011) Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice. Journal of Pharmaceutical and Biomedical Analysis 56: 1117-1120

Oussenko IA, Holland JF, Reddy EP, Ohnuma T (2011) Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation. Cancer Res 71: 4968-4976

Reddy MVR, Venkatapuram P, Mallireddigari MR, Pallela VR, Cosenza SC, Robell KA, Akula B, Hoffman BS, Reddy EP (2011) Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (E)-2-{2-Methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl] phenylamino} acetate (ON 01910.Na): Synthesis, Structure-Activity Relationship, and Biological Activity. Journal of Medicinal Chemistry 54: 6254-6276

Cho SY, Ohnuma T, Silverman LR, Holland JF, Roboz J (2010) Discontinuous Drug Binding to Proteins: Binding of an Antineoplastic Benzyl Styryl Sulfone to Albumin and Enzymes in Vitro and in Phase I Clinical Trials. Drug Metab Dispos 38: 1480-1485

Jimeno A, Rubio-Viqueira B, Rajeshkumar NV, Chan A, Solomon A, Hidalgo M (2010) A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Mol Cancer Ther 9: 311-318

Chun AW, Cosenza SC, Taft DR, Maniar M (2009) Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother Pharmacol 65: 177-186

Prasad A, Park IW, Allen H, Zhang X, Reddy MVR, Boominathan R, Reddy EP, Groopman JE (2009) Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene 28: 1518-1528

Kang AD, Cosenza SC, Bonagura M, Maniar M, Reddy MVR, Ren Q, Rodeck U, Reddy EP (2013) ON 01210.Na (Ex-RAD®) mitigates radiation damage through activation of the AKT pathway. PLOS 8: e58355

Ghosh SP, Kulkarni S, Perkins MW, Hieber K, Pessu RL, Gambles K, Maniar M, Kao TC, Seed TM, Kumar KS (2012) Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RAD^® in mice. Journal of Radiation Research 53(4): 526-536

Suman S, Datta K, Doiron K, Ren C, Kumar R, Taft DR, Fornace AJ, Jr., Maniar M, (2012) Radioprotective Effects of ON 01210.Na upon Oral Administration. Journal of Radiation Research 53(3): 368-376

Suman S, Maniar M, Fornace AJ, Jr., Datta K (2012) Administration of ON 01210.Na after exposure to ionizing radiation protects bone marrow cells by attenuating DNA damage response. Radiation Oncology 7(1): 6-14

Tamhane M, Maniar M, Ren C, Benzeroul KE, Taft DR (2012) Disposition of ON 01210.Na (Ex-RAD^®), a Novel Radioprotectant, in the Isolated Perfused Rat Liver: Probing Metabolic Inhibition to Increase Systemic Exposure. J Pharmaceut Sci: ePub 4Dec2012

Chun AW, Freshwater RE, Taft DR, Gillum AM, Maniar M (2011) Effects of formulation and route of administration on the systemic availability of Ex-RAD^®, a new radioprotectant, in preclinical species. Biopharmaceutics & Drug Disposition 32(2): 99-111

Ghosh SP, Perkins MW, Hieber K, Kulkarni S, Kao TC, Reddy EP, Reddy MVR, Maniar M, Seed T, Kumar KS (2009) Radiation protection by a new chemical entity, Ex- RAD^™: efficacy and mechanisms. Radiat Res 171(2): 173-179

Fernandes PP, Maniar M, Dash AK (2007) Development and validation of a sensitive liquid chromatographic method for the analysis of a novel radioprotectant: ON 01210.Na. J Pharm Biomed Anal 43(5): 1796-1803

Singh VK, Ducey EJ, Brown DS, Whitnall MH (2012) A review of radiation countermeasure work ongoing at the Armed Forces Radiobiology Research Institute. International journal of radiation biology 88(4): 296-310

Thayer AM (2012) The Drugs That May Never Be Used. Chemical & Engineering News 90(26): 23-26

Willyard C (2011) Nuclear leak reinforces need for drugs to combat radiation. Nat Med 17(4): 391